雌激素受体作为一种预后预测指标，加入到了其他癌症生物标志物的行列。
The estrogen receptor joins other cancer biomarkers as a predictor of outcome.
作者信息
Leslie Kimberly K, Thiel Kristina W, Reyes Henry D, Yang Shujie, Zhang Yuping, Carlson Matthew J, Kumar Nirmala S, Dai Donghai D
机构信息
Department of Obstetrics and Gynecology, University of Iowa Hospitals and Clinics, 200 Hawkins Drive, Iowa City, IA 52242, USA.
出版信息
Obstet Gynecol Int. 2013;2013:479541. doi: 10.1155/2013/479541. Epub 2013 Oct 7.
Endometrial cancer, the most common gynecologic malignancy in the United States, is on the rise, and survival is worse today than 40 years ago. In order to improve the outcomes, better biomarkers that direct the choice of therapy are urgently needed. In this review, we explore the estrogen receptor as the most studied biomarker and the best predictor for response for endometrial cancer reported to date.
子宫内膜癌是美国最常见的妇科恶性肿瘤，其发病率正在上升，且如今的生存率比40年前更差。为了改善治疗结果，迫切需要能指导治疗选择的更好的生物标志物。在本综述中，我们探讨雌激素受体，它是迄今为止报道的对子宫内膜癌研究最多的生物标志物和最佳反应预测指标。
Zotero 插件